Related Experiment Video

Updated: Jan 30, 2026

Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

1.0K

Existing and emerging treatments for idiopathic pulmonary fibrosis

Lykourgos Kolilekas1, Spyridon Papiris2, Demosthenes Bouros3

  • 1a 7th Department of Pneumonology , Hospital for Diseases of the Chest, "Sotiria" , Athens , Greece.

Expert Review of Respiratory Medicine
|January 12, 2019
PubMed
Abstract

Insights

Current treatments for idiopathic pulmonary fibrosis (IPF) slow disease progression but do not cure it. Emerging therapies show promise for improving patient outcomes and quality of life.

Area of Science:

  • Pulmonology
  • Pharmacology
  • Interstitial Lung Diseases

Background:

  • Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal lung disease with limited curative options.
  • Current antifibrotic therapies can halt IPF progression but do not reverse or cure the condition.
  • Recent advancements in understanding IPF pathogenesis have identified novel therapeutic targets.

Purpose of the Study:

  • To review current and emerging pharmacological therapies for IPF.
  • To discuss investigational compounds in clinical trials (Phase II-IV) for IPF.
  • To highlight the potential of new treatments to improve IPF patient prognosis.

Main Methods:

  • Literature review of current and emerging IPF pharmacological therapies.
  • Analysis of clinical trial data for promising investigational compounds.
  • Synthesis of expert commentary on the future of IPF treatment.

Main Results:

  • Existing IPF therapies effectively slow disease progression.
  • Numerous clinical trials are investigating targeted biologic pathways for IPF.
  • Several promising compounds show positive or pending trial results.

Conclusions:

  • While a definitive cure for IPF is not imminent, new therapeutic targets are being explored.
  • Personalized medicine, akin to an 'oncologic approach,' may enhance IPF patient survival and quality of life.
  • Ongoing research and clinical trials offer hope for improved management of idiopathic pulmonary fibrosis.
Keywords:
Idiopathic pulmonary fibrosispathogenetic mechanismsusual interstitial pneumonia

More Related Videos

Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo06:29

Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo

Published on: May 5, 2023

3.1K
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

1.8K

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
600
Emerging Adulthood01:27

Emerging Adulthood

Jeffrey Arnett's concept of emerging adulthood offers a framework to understand the unique developmental stage between adolescence and full-fledged adulthood, generally from ages 18 to 25. This period is marked by extensive exploration and shifts in identity, relationships, and career choices, a process known in psychology as role experimentation. Emerging adulthood reflects the evolving cultural expectations surrounding adulthood and the dynamic process of personal transformation during...
681
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
464
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
507
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
616
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
871